Table 3.
Association of the BRCA1/2-mutations with clinicopathologic characteristics in 141 ovarian cancer patients.
| Clinicopathologic characteristics | BRCA1/2-mutation Type (cases) |
BRCA1/2-wild type (cases) | P value |
|---|---|---|---|
| Age (year) | 0.218 | ||
| ≤40 | 7.4% (2/27) | 4.4% (5/114) | |
| 40-49 | 37% (10/27) | 21.0% (24/114) | |
| 50-59 | 37% (10/27) | 44.8% (51/114) | |
| ≥60 | 18.5% (5/27) | 29.8% (34/114) | |
| FIGO staging | 0.649 | ||
| I-II | 18.5% (5/27) | 16.7% (19/114) | |
| III-IV | 77.8% (21/27) | 64.9% (74/114) | |
| Unknown | 3.7% (1/27) | 18.4% (21/114) | |
| Serum CA125 | 0.426 | ||
| High | 81.5% (22/27) | 77.2% (88/114) | |
| Normal | 18.5% (5/27) | 22.8% (26/114) | |
| Family history | 0.134 | ||
| Presence | 14.8% (4/27) | 6.1% (7/114) | |
| Absence | 85.2% (23/27) | 93.9% (107/114) | |
| Personal history | 0.682 | ||
| Presence | 14.8% (4/27) | 4.4% (5/114) | |
| Absence | 85.2% (23/27) | 95.6% (109/114) | |
| Distant metastasis | 0.002 | ||
| Presence | 70.4% (19/27) | 37.7% (43/114) | |
| Absence | 29.6% (8/27) | 62.3% (71/114) | |
| Ki67 protein | 0.869 | ||
| Positive | 66.7% (18/27) | 45.6% (52/114) | |
| Negative | 11.1% (3/27) | 13.2% (15/114) | |
| Unknown | 22.2% (6/27) | 41.2% (47/114) |